We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
For all its landmark status, lecanemab may end up representing a triumph of hope over evidence
High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially
Lars Lannfelt had a key role in developing a drug that has shown some promise in tackling Alzheimer’s
Dementia drug development, diagnostics and delivery still require much more investment
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Shares fall 11% following two patient deaths in trials of lecanemab
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
Pharma groups seek US regulatory approval as clinical trial shows monoclonal antibody treatment slowed disease
‘Hard numbers’ model designed by ex-head of finance is winning followers among leading investors and corporate Japan
Hypothesis that brain plaques cause disease viewed with scepticism by some scientists
Eisai says framework for testing and treatment urgently needed in response to ‘secret pandemic’
Biogen’s aducanumab was last hope of one approach to the disease, but there are others
Drugmaker loses $18bn from market value after deciding to discontinue trials
Costs are irrecoverable in industry that has to plan for all possible scenarios
Japanese group’s tie-up with US pharma on cancer drug will boost its research on Alzheimer’s
The cost of new drugs is pushing health budgets to the limit
Health service poised to stop paying for expensivecostly cancer therapies
Health service expected to stop paying for some expensive treatments
International Edition
